Frontlight ResearchEarly access
Taking peopleNo phase
Histotripsy for Renal Cell Carcinoma
Key facts
- Who runs it
- The University of Hong Kong
- Where
- Hong Kong1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 15 people, planned
- Started
- 13 Oct 2026
- Expected to end
- 30 Oct 2029
- Type of study
- Interventional
- Treatments tested
- HistoSonics® Edison System (US)
- Record updated
- 17 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Age ≥ 18 years old
- Fit for general anaesthesia
- Histologically confirmed renal cell carcinoma; radiological diagnosis acceptable if biopsy is not feasible
- With or without distant metastases
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) grade 0-2
- Tumour visible and targetable by ultrasound with acceptable acoustic windows
- Adequate hematologic, hepatic, and renal function (eGFR ≥45mL/min, ≤14 days prior to the planned index procedure date)
Who cannot take part
- Poor general condition with limited life expectancy
- Refusal to take part in clinical trial
- Not fit for general anaesthesia
- Uncontrolled coagulopathy
- The treatment of the tumour will not allow for an adequate margin as determined by the investigator
This trial is currently available in Hong Kong.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The project will be a pilot study in localised or metastatic renal cell carcinoma, assessing safety, local control, and exploratory immune endpoints. Outcomes from this work will inform rational combinations with targeted agents and immune checkpoint blockade and may define a new, image-guided, non-invasive modality for renal cell carcinoma. If successful, histotripsy could become a new non-thermal, local therapy for renal cell carcinoma with dual benefits of debulking and immune activation achieving strong clinical and scientific impact.
The group in the trial
- Patients receiving Histotripsy procedure for renal cell cancer using the HistoSonics® Edison SystemTreatment being tested
Treatment: HistoSonics® Edison System (US)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Histotripsy for Renal Cell Carcinoma: a Pilot Study for a Novel Focused Therapy With an Unmet Need
- Record updated
- 17 November 2026